A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Donald Strickland, M.D.
Genentech, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
247 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cemic
Buenos Aires, Argentina
- Hospital Britanico
Buenos Aires, Argentina
- Hospital Pirovano
Buenos Aires, Argentina
- Hospital Toru
Buenos Aires, Argentina
- Centro Oncologico de Cordoba
Córdoba, Argentina
- Coir
Mendoza, Argentina
- Instituto Medico Privado
Resistencia, Argentina
- Clinica Oncologica de Rosario
Rosario, Argentina
- Isis Clinica Especializada
Sante Fe, Argentina
- Holy Spirit Hospital Northside
Chermside, QLD, Australia
- Sunshine Coast Cancer Centre
Nambour, QLD, Australia
- Sir Charles Gairdner Hospital
Nedlands, WA, Australia
- Burnside War Memorial Hospital
Toorak Gardens, SA, Australia
- Cliniques Univ St Luc
Brussels, Belgium
- Chr Citadelle Liege
Liège, Belgium
- Instituto de Cancer Arnaldo
São Paulo, São Paulo, Brazil
- Instituto Nacional Do Cancer
Rio de Janeiro, Brazil
- Hospital Das Clinicas
São Paulo, Brazil
- Regional Oncodispensary
Plovdiv, Bulgaria
- Regional Oncodispensary
Rousse, Bulgaria
- Regional Oncodispensary
Shumen, Bulgaria
- National Specialized Hospital
Sofia, Bulgaria
- Regional Oncodispensary
Sofia, Bulgaria
- Umhat "queen Joanna"
Sofia, Bulgaria
- Regional Oncodispensary
Stara Zagora, Bulgaria
- Mhat "st Marina"
Varna, Bulgaria
- Regional Oncodispensary
Veliko Tarnovo, Bulgaria
- Princess Margaret Hospital
Hong Kong, Hong Kong
- Queen Elizabeth Hospital
Hong Kong, Hong Kong
- Queen Mary Hospital
Hong Kong, Hong Kong
- Tuen Mun Hospital
Hong Kong, Hong Kong
- Hadassah Medical Center
Jerusalem, Israel
- Sourasky Medical Center
Tel Aviv, Israel
- Sheba Medical Center
Tel Litwinsky, Israel
- Azienda Ospedaliera Univ
Genova, Italy
- Ist Nazion Per Ricerca Cancro
Genova, Italy
- Univ Degli Studi Di Napoli
Naples, Italy
- Azienda Ospedaliera
Parma, Italy
- Azienda Osper Di Perugia
Perugia, Italy
- Divisione Onc Med Dell'Azienda
Udine, Italy
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2006
- Primary completion
- 30 Nov 2014
- Completion
- 30 Nov 2014
- Last update posted
- 18 Apr 2016
- Registered enrollment
- 1,145
- Registry id
- NCT00257608
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.